Search

EP-4734940-A1 - A PERSONAL CARE COMPOSITION BASED ON CARBOXYMETHYL CYSTEINE COMPOUND AND ROSMARINIC ACID OR SALT AND ESTER THEREOF

EP4734940A1EP 4734940 A1EP4734940 A1EP 4734940A1EP-4734940-A1

Abstract

Disclosed is a personal care composition comprising carboxymethyl cysteine compound and rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof, wherein the molar ratio of the carboxymethyl cysteine compound to total rosmarinic acid compound is no greater than 25:1.

Inventors

  • GU, Xuelan
  • XIAO, XUE
  • ZHANG, HONG

Assignees

  • Unilever IP Holdings B.V.
  • UNILEVER GLOBAL IP LIMITED

Dates

Publication Date
20260506
Application Date
20240524

Claims (13)

  1. 1. A personal care composition comprising carboxymethyl cysteine compound and rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof, wherein the molar ratio of the carboxymethyl cysteine compound to total rosmarinic acid compound is no greater than 25:1.
  2. 2. The composition according to claim 1 wherein the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
  3. 3. The composition according to claim 2 wherein the carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine and preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate.
  4. 4. The composition according to any one of the preceding claims wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition, preferably carboxymethyl cysteine compound is present in amount of at least 0.01% and no greater than 3% by weight of the composition.
  5. 5. The composition according to any one of the preceding claims wherein the rosmarinic acid compound is selected from rosmarinic acid and salt thereof, preferably the rosmarinic acid compound is rosmarinic acid.
  6. 6. The composition according to any one of the preceding claims wherein the amount of the rosmarinic acid compound is from 0.001 to 5%, preferably from 0.05 to 1 .5% by weight of the total amount of the composition.
  7. 7. The composition according to any one of the preceding claims wherein the molar ratio of the carboxymethyl cysteine compound to the rosmarinic acid compound is in the range of 1 :5 to 15:1 , preferably in the range of 3.5:1 to 8:1.
  8. 8. The composition according to any one of the preceding claims wherein the molar ratio of the lysine carboxymethyl cysteinate to the rosmarinic acid is in the range of 1 :5 to 15: 1 , preferably in the range of 3.5: 1 to 8: 1.
  9. 9. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion.
  10. 10. The composition according to any one of the preceding claims wherein the composition is a fluid liquid at 25 °C and atmospheric pressure.
  11. 11 . The composition according to any one of the preceding claims wherein the composition comprises water in amount of 10 to 96% by weight of the composition, preferably from 42 to 88% by weight of the composition.
  12. 12. A method of providing the skin benefits selected from the group consisting of improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging and upregulating the expression of cellular retinoic acid-binding protein II gene comprising a step of topically applying to the skin the composition of any one of the preceding claims.
  13. 13. Use of the composition of any one of the preceding claims 1 to 11 for providing the skin benefits selected from the group consisting of improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging and upregulating the expression of cellular retinoic acid-binding protein II gene.

Description

A PERSONAL CARE COMPOSITION BASED ON CARBOXYMETHYL CYSTEINE COMPOUND AND ROSMARINIC ACID OR SALT AND ESTER THEREOF Field of the Invention The present invention relates to a personal care composition. In particular the present invention is related to a personal care composition comprising carboxymethyl cysteine compound and rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof. It was surprisingly found that the expression of CRABPII gene was significantly elevated when the molar ratio of the carboxymethyl cysteine compound to the total rosmarinic acid compound is within a certain range. Background of the Invention The skin is a primary barrier of the human body. It protects the organs in the body from external stimulations. It is subject to intrinsic aging and extrinsic aging. Skin aging is a complex process, and alterations in human skin due to aging have distinct characteristics as compared to other organs. Characteristics of intrinsic or chronological skin aging include dryness, visible free lines and wrinkles, uneven skin pigmentation, loss of elasticity and skin sagging. Extrinsic factors including exposure to sunlight, pollutants and cigarette smoke can accelerate the skin aging process, especially on the face. Retinoids (e.g. retinol and retinyl esters) are common ingredients used in personal care products. Retinol (vitamin A) is an endogenous compound which occurs naturally in the human body and is essential for epidermal cell growth and differentiation and are beneficial to counteract skin aging. Natural and synthetic vitamin A derivatives have been used extensively in the treatment of a variety of skin disorders and have been used as skin repair or renewal agents. The cellular retinoic acid-binding protein II (CRABPII) facilitates the passage of all-trans-retinoic acid (and related derivatives) through the cytoplasm to access retinoic acid receptors. Upregulating the expression of CRABPII gene typically leads to an increase in production of cellular retinoic acidbinding protein II and therefore helps anti-aging. Therefore, the present inventors have recognized that there is a need to develop solution to upregulate the expression of CRABPII gene. It was surprisingly found that by combining carboxymethyl cysteine compound and rosmarinic acid compound, the expression of CRABPII gene was significantly upregulated. Summary of the Invention In a first aspect, the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof, wherein the molar ratio of the carboxymethyl cysteine compound to the total rosmarinic acid compound is no greater than 25:1. In a second aspect, the present invention is directed to a method of providing the skin benefits selected from the group consisting of improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging and upregulating the expression of cellular retinoic acidbinding protein II gene comprising a step of topically applying to the skin the composition of the composition of the present invention. In a third aspect, the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging and upregulating the expression of cellular retinoic acid-binding protein II gene. All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow. Detailed Description of the Invention Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and/or use may optionally be understood as modified by the word “about”. All amounts are by weight of the composition, unless otherwise specified. It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value. For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of’. In other words, the listed steps or options need not be exhaustive. The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy. Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis. The carboxymethyl cysteine compound refers to compound selected from carboxymethyl cystei